<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241305</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5510</org_study_id>
    <secondary_id>U54AR057319-06</secondary_id>
    <nct_id>NCT01241305</nct_id>
  </id_info>
  <brief_title>One-Time DNA Study for Vasculitis</brief_title>
  <official_title>VCRC Genetic Repository One-Time DNA Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify genes that increase the risk of developing&#xD;
      vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of&#xD;
      these studies will provide vasculitis researchers with insight into the causes of these&#xD;
      diseases and generate new ideas for diagnostic tests and therapies, and will be of great&#xD;
      interest to the larger communities of researchers investigating vasculitis and other&#xD;
      autoimmune, inflammatory, and vascular diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The systemic vasculitides comprise several inflammatory diseases of blood vessels, usually&#xD;
      arteries, which may cause systemic, multi-organ disease that can result in substantial&#xD;
      morbidity and increased mortality. Each type of vasculitis is a rare (&quot;orphan&quot;) disease.&#xD;
      However, taken together, vasculitis affects tens of thousands of Americans and is responsible&#xD;
      for substantial morbidity and mortality and almost one billion dollars per year in hospital&#xD;
      care alone. While the vasculitides share the trait of vascular inflammation, the unique&#xD;
      disease phenotypes, clinical courses, differences in prognoses, and responses to therapy&#xD;
      suggest that important differences exist in pathogenesis. The Vasculitis Clinical Research&#xD;
      Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to&#xD;
      represent a balance between unmet medical and scientific needs, prevalence in North America,&#xD;
      feasibility of study, and an interest in studying a spectrum of small, medium, and large&#xD;
      vessel vasculitides.&#xD;
&#xD;
      The great majority of published studies on the genetics of vasculitis have used modest-sized&#xD;
      cohorts that are only suitable for investigation of a few candidate genes at a time, or to&#xD;
      detect large effect sizes, so that replicated findings are highly skewed to the HLA region.&#xD;
      Larger and more ambitious genetic studies in vasculitis are expected to generate numerous&#xD;
      hypotheses for translational research in gene expression, biochemistry, and molecular&#xD;
      pathology.&#xD;
&#xD;
      A one-time collection of clinical data and DNA would substantially increase the sample sizes&#xD;
      for genetic association studies in all six vasculitides studied in the VCRC. Many patients&#xD;
      are seen at participating VCRC centers but do not enroll in the Longitudinal Studies. These&#xD;
      patients often are interested in participating in research studies but cannot return&#xD;
      frequently for visits, usually due to distance from the VCRC centers. This approach would be&#xD;
      particularly useful for the rarer forms of vasculitis under study (Takayasu's Arteritis&#xD;
      (TAK), Polyarteritis Nodosa (PAN), eosinophilic granulomatosis with polyangiitis&#xD;
      (Churg-Strauss) (EGPA) and also for Giant Cell Arteritis (GCA), since elderly patients have&#xD;
      been particularly likely to decline participation in the Longitudinal Studies due to travel&#xD;
      constraints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of clinical data and linked DNA specimens.</measure>
    <time_frame>1 year.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)</condition>
  <condition>Giant Cell Arteritis</condition>
  <condition>Granulomatosis With Polyangiitis (Wegener's)</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Polyarteritis Nodosa</condition>
  <condition>Takayasu's Arteritis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 10 ml tubes of blood will be collected for DNA extraction.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa,&#xD;
        granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and eosinophilic&#xD;
        granulomatosis with polyangiitis (Churg-Strauss). Enrollment will be sequential and&#xD;
        patients will have disease in various stages and of different duration.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset &gt;50 years (required)&#xD;
&#xD;
          1. New onset or new type of localized pain in the head&#xD;
&#xD;
          2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased&#xD;
             pulsation, unrelated to arteriosclerosis of cervical arteries)&#xD;
&#xD;
          3. ESR of &gt;40mm in the first hour by the Westergren method&#xD;
&#xD;
          4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized&#xD;
             by a predominance of mononuclear cell infiltration or granulomatous inflammation,&#xD;
             usually with multinucleated giant cells)&#xD;
&#xD;
          5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        2. Diagnostic criteria for Takayasu's Arteritis&#xD;
&#xD;
          1. Age at disease onset &lt;50 years&#xD;
&#xD;
          2. Claudication of extremities&#xD;
&#xD;
          3. Decreased brachial artery pulse (one or both arteries)&#xD;
&#xD;
          4. Blood pressure difference of &gt;10mm Hg between the arms&#xD;
&#xD;
          5. Bruit over subclavian arteries or aorta&#xD;
&#xD;
          6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography&#xD;
             or MR angiography or CT angiography)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other&#xD;
        causes) felt by investigator to be due to vasculitis&#xD;
&#xD;
          1. Arteriographic abnormality&#xD;
&#xD;
          2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy&#xD;
&#xD;
          3. Mononeuropathy or polyneuropathy&#xD;
&#xD;
        Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis&#xD;
&#xD;
          1. Weight loss &gt; 4 kg&#xD;
&#xD;
          2. Livedo reticularis, cutaneous ulcerations, or skin nodules&#xD;
&#xD;
          3. Testicular pain or tenderness&#xD;
&#xD;
          4. Myalgias&#xD;
&#xD;
          5. Diastolic blood pressure &gt; 90 mm Hg&#xD;
&#xD;
          6. Elevated BUN or serum creatinine levels&#xD;
&#xD;
          7. Ischemic abdominal pain&#xD;
&#xD;
        Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and&#xD;
        Microscopic Polyangitis (MPA)&#xD;
&#xD;
          -  Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to&#xD;
             classification criteria or definitions, have not been developed for GPA &amp; MPA.&#xD;
&#xD;
          -  For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:&#xD;
&#xD;
               1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood&#xD;
&#xD;
               2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities&#xD;
&#xD;
               3. Urinary sediment with microhematuria or red cell casts&#xD;
&#xD;
               4. Granulomatous inflammation within the wall of an artery or in the perivascular&#xD;
                  area on biopsy&#xD;
&#xD;
               5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for&#xD;
                  either PR3- or MPO-ANCA&#xD;
&#xD;
          -  For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:&#xD;
&#xD;
               1. Necrotizing vasculitis, with few or no immune deposits, that affects small&#xD;
                  vessels (i.e., capillaries, venules, arterioles)&#xD;
&#xD;
               2. Necrotizing arteritis involving small- and medium-sized arteries may be present&#xD;
&#xD;
               3. Necrotizing glomerulonephritis is very common&#xD;
&#xD;
               4. Pulmonary capillaritis often occurs&#xD;
&#xD;
                  Inclusion Criteria:&#xD;
&#xD;
                  5. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis&#xD;
                  (Churg-Strauss)&#xD;
&#xD;
                    1. Asthma&#xD;
&#xD;
                    2. Peak peripheral blood eosinophilia of &gt;10% of total WBC&#xD;
&#xD;
                    3. Peripheral neuropathy attributable to vasculitis&#xD;
&#xD;
                    4. Transient pulmonary infiltrates on chest imaging studies&#xD;
&#xD;
                    5. Paranasal sinus abnormalities or nasal polyposis&#xD;
&#xD;
                    6. Eosinophilic inflammation on tissue biopsy&#xD;
&#xD;
                  If patients have 4 of the above 6 criteria but lack clearcut documentation of&#xD;
                  small vessel vasculitis, they are also eligible for enrollment.&#xD;
&#xD;
                  General Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent and to sign the consent form&#xD;
&#xD;
          -  Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523&#xD;
&#xD;
          -  Unwilling to provide blood for DNA collection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Merkel, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol McAlear, MA</last_name>
    <email>cmcalear@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loretta Williams</last_name>
      <email>WILLIAL34@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gillespie</last_name>
      <email>Sarah.Hopkins@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35873</phone_ext>
      <email>smessier@stjoes.ca</email>
    </contact>
    <investigator>
      <last_name>Nader Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Khurana</last_name>
      <email>Suneet.Khurana@sinaihealth.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Carette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <state>Fatih</state>
        <zip>34452</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>CSS</keyword>
  <keyword>EGPA</keyword>
  <keyword>GCA</keyword>
  <keyword>GPA</keyword>
  <keyword>WG</keyword>
  <keyword>MPA</keyword>
  <keyword>PAN</keyword>
  <keyword>TAK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Polyarteritis Nodosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

